Section Arrow
Quote
ACIU.NASDAQ
- AC Immune SA
Quotes are at least 15-min delayed:2026/06/20 19:21 EDT
Regular Hours
Last
 2.4
+0.06 (+2.56%)
Day High 
2.425 
Prev. Close
2.34 
1-M High
3.03 
Volume 
213.33K 
Bid
2.28
Ask
2.44
Day Low
2.335 
Open
2.4 
1-M Low
2.095 
Market Cap 
238.15M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.28 
20-SMA 2.5 
50-SMA 2.79 
52-W High 4 
52-W Low 1.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.66/0.17
Enterprise Value
241.84M
Balance Sheet
Book Value Per Share
0.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.57M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.01+0.0056+127.27%-- 
CDTCDT Equity Inc.1.02+0.327+47.19%-- 
AZTRAzitra0.1717-0.0313-15.42%-- 
CRVOCervoMed4.24+0.43+11.29%-- 
OCGNOcugen1.24+0.01+0.81%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.